Navigation Links
Simcere Pharmaceutical Group to Announce Second Quarter 2012 Financial Results on Friday, August 10, 2012
Date:7/30/2012

NANJING, China, July 30, 2012 /PRNewswire-Asia/ -- Simcere Pharmaceutical Group (NYSE: SCR), a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today announced that it will report its unaudited financial results for the second quarter ended June 30, 2012 on Friday, August 10, 2012, before the market opens in the United States. Simcere's management will host an earnings conference call on the same day at 8 a.m. ET (Friday, August 10, at 8 p.m. Beijing/Hong Kong time).

To access the conference call, please dial:International toll:

+65.6723.9381United States toll-free:

+1.866.519.4004United States toll:

+1.718.354.1231China Domestic toll:

800.819.0121 China Domestic mobile toll:

400.620.8038 Hong Kong toll:

+852.2475.0994Please ask to be connected to Q2 2012 Simcere Pharmaceutical Group Earnings Conference Call and provide the following passcode: 15292591. Simcere will also broadcast a live audio webcast of the conference call. The broadcast will be available by visiting the "Investor Relations" section of the company's web site at www.simcere.com.

Following the earnings conference call, an archive of the call will be available by dialing:United States toll-free:

+1.866.214.5335United States toll:

+1.718.354.1232The passcode for replay participants is 15292591. The telephone replay also will be archived on the "Investor Relations" section of the company's website for seven days following the earnings announcement.

About Simcere Pharmaceutical GroupSimcere Pharmaceutical Group (NYSE: SCR, Simcere) is a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded and proprietary pharmaceuticals in China. Simcere concentrates its research and development efforts on the treatment of diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective pharmacotherapy such as cancer, strokes, cardiovascular disease, infectious diseases and pain. For more information about Simcere Pharmaceutical Group, please visit www.simcere.com.Investor and Media Contacts: Email: ir@simcere.com In Nanjing:In the United States:Yehong Zhang

Cindy ZhengPresident

Brunswick GroupSimcere Pharmaceutical Group

Tel: 1-212-333-3810Tel: 86-25-8556-6666 ext. 8811In Beijing:In Hong Kong:Yue Yu

Joseph Lo Chi-LunBrunswick Group

Brunswick GroupTel: 86-10-5960-8600

Tel: 852-3512-5000   


'/>"/>
SOURCE Simcere Pharmaceutical Group
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Simcere Pharmaceutical Group Provides Notice of Annual General Meeting
2. Simcere Pharmaceutical Group to Announce First Quarter 2012 Financial Results on Wednesday, May 9, 2012
3. Pharmaceutical Manufacturers Attempt to Safeguard Business Continuity from Potential Threats and Disasters to Production
4. Stephen G. Austin, CPA Joins Imprimis Pharmaceuticals Board Of Directors
5. Jason Pharmaceuticals, Inc. Reaches Proposed Consent Agreement with FTC
6. Cadence Pharmaceuticals To Host Conference Call And Webcast To Discuss Second Quarter 2012 Financial Results On August 2, 2012
7. GDS Internationals Fourth Next Generation Pharmaceutical Drug Development Summit Attracts an Unprecedented Delegation of Thought Leaders
8. ADVENTRX Pharmaceuticals to Present at 1st Annual Sickle Cell Disease Therapeutics Conference
9. Actinium Pharmaceuticals Inc. Pays Regulatory Milestone to Abbott Biotherapeutics Corp.
10. Anthera Pharmaceuticals Announces Exercise in Full of Over-Allotment Option and Completion of Public Offering of Common Stock
11. Avion Pharmaceuticals, LLC., Launches Prenate Mini
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... -- Entscheidung fällt als Reaktion ... Die internationale humanitäre Stadt soll um knapp 2800 m² erweitert ... Seine Hoheit Scheich Muhammad bin Raschid Al ... Dubai , hat den Auftrag erteilt, ... City IHC) zu verdreifachen, um den Betrieb zur Unterstützung ...
(Date:1/19/2017)... 19, 2017 The global immunomodulators market ... 2025, according to a new study by Grand ... be predominantly driven by high R&D investments employed ... production of new and therapeutically advanced drugs. This ... at an unprecedented rate into the immunomodulators market ...
(Date:1/19/2017)... 19, 2017 The U.S. Food and Drug Administration ... Constipation (CIC) in adult patients. "No one ... said Julie Beitz , M.D., director of the Office ... Evaluation and Research. "With the availability of new therapies, patients ... their condition." ...
Breaking Medicine Technology:
(Date:1/21/2017)... ... 2017 , ... "ProDOF is the perfect set of tools for video editors that want to ... said Christina Austin - CEO of Pixel Film Studios. , Video editors using ProDOF ... of a DSLR racking focus from one area into the next. ProDOF comes with ...
(Date:1/21/2017)... Rosa, CA (PRWEB) , ... January 21, 2017 ... ... announce that Redwood Family Dermatology has recently joined their multi-specialty medical ... a full range of cosmetic services. , “We’re excited to add this excellent ...
(Date:1/20/2017)... ... ... Spectrum Aquatics Launches New ADA Portable Motion Trek BP 300 Lift. Built for durability, this ... wheels, it can be wheeled out of the way and stored when not in use. ... have transformed the feedback from customers into specific enhancements and created a new product that ...
(Date:1/20/2017)... ... , ... Doctor C LLC, a company based out of Arizona that focuses ... the marketing and distribution of its product, The Right C. , The Right C ... than traditional vitamin C supplements. At the trade show, Doctor C had the opportunity ...
(Date:1/20/2017)... Boca Raton, FL (PRWEB) , ... January 20, 2017 , ... ... highest level of nutritional and bodybuilding supplements, announced it attended the January ECRM trade ... a respected bodybuilder and nutritional scientist who was determined to create a line of ...
Breaking Medicine News(10 mins):